Milestone Pharmaceuticals Inc CARDAMYST Investor Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Santos Luis - H.C. Wainwright & Co., LLC - Analyst : Hi, Luis Santos here from HC Wainwright in for Patrick Chuy as well. Again, congratulations on the progress you've been doing and everything you've handled from the first NDA handling all of the ramp up into what we hope is going to be a positive outcome in the, in March. Everything that's in your hands and the execution that you're planning is on point and we're very positive on that. My questions are focused on what might not be on your hands, which is the potential for electrophysiologists to have those two scenarios of switching, for, so using CARDAMYST for bridging to an ablation or even and as an alternative to an ablation, and you said 30, around 33, 1/3 EPS will suggest the bridging. Now how and you anticipated achieving a target population within the three years of launch and I just, my numbers are not meeting within those three years if it's just 1/3 of the EPS suggesting that use. The other one in line with that is the reductions. In visits the expected reductions in visits, clinical visits by using CARDAMYST, which was about 40%, even if it's 50%. So how does this come into the expected ramp up in the next 3 years to achieve that target population. Thank you.